GranuFlo Recall

On March 29, 2012, the German company Fresenius Medical Care sent a memo to its customers advising them that its dialysate product GranuFlo might cause heart attacks and other side effects. In late June 2012, the U.S. Food and Drug Administration (FDA) classified Fresenius’s memo as a class I recall, the FDA’s most significant kind.

Metabolic Alkalosis Risk Cited as Cause For Recall

According to the FDA’s GranuFlo recall announcement, when used to treat people with kidney ailments, excess doses of GranuFlo can lead to high levels of serum bicarbonate, an alkaline chemical. Because the human body must maintain a certain pH balance to function properly, excess bicarbonate can cause a condition called metabolic alkalosis, which in turn can cause “low blood pressure, hypokalemia, hypoxemia, hypercapnia and cardiac arrhythmia, which, if not appropriately treated, may culminate in cardiopulmonary arrest.”

The recall affects GranuFlo products that Fresenius manufactured and distributed between January 2008 and June 2012.

RLG’s GranuFlo Lawyers Will Advocate for You

If you received recalled GranuFlo as part of your hemodialysis treatment and believe it caused an injury, you might be entitled to compensation from the manufacturer. Submit this simple secure form for a free and confidential evaluation of your eligibility to file a GranuFlo lawsuit. The Rottenstein Law Group will consult with you for free, possibly filing a lawsuit on your behalf and keeping you up to date on any GranuFlo class action lawsuits, new FDA GranuFlo warnings, and additional GranuFlo FDA recall announcements. You will not be charged a penny until you receive compensation for your injurues.

Join the Discussion

Please note: Comments are encouraged in order to permit visitors to discuss relevant topics. Comments are moderated and might be edited by RLG before being published.

Comments should not be used to ask questions of RLG’s lawyers; if you want to speak with a lawyer, please fill out this contact form or call 1 (888) 976-8529. *Your name and email address will not be published.

*

  

RLG encourages you to reproduce our original content—on your own web site; in emails to your friends and family; in blogs, posts, and tweets, etc.—but we ask that you please attribute whatever you use to us, and, whenever possible, provide a link to the page where you first found the material. That way, whoever reads your excerpt might read more informative material of interest at one of RLG's sites.
You’ve taken enough. We'll take it from here. Click here to contact us now.